Rainer Hambrecht
Overview
Explore the profile of Rainer Hambrecht including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
157
Citations
6290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bavendiek U, Berliner D, Thomas N, Liu X, Schwab J, Rieth A, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39838553
No abstract available.
2.
Eitel I, Saraei R, Jurczyk D, Fach A, Hambrecht R, Wienbergen H, et al.
Eur Heart J
. 2024 Sep;
45(47):5058-5067.
PMID: 39217605
Background And Aims: Glycoprotein (GP) IIb/IIIa inhibitors are recommended in acute myocardial infarction (AMI) for bailout treatment in case of angiographic microvascular obstruction (MVO), also termed no-reflow phenomenon, after percutaneous...
3.
Kerniss H, Marin L, Clemens K, Litfin C, Seidel-Sarpong A, Hanses U, et al.
Clin Res Cardiol
. 2024 Jun;
PMID: 38896124
Background: International guidelines emphasize the importance of preventive efforts after early-onset myocardial infarction (EOMI); however, data on "real-world" long-term risk factor management and adverse event rates in this special patient...
4.
Heer T, Zeymer U, Hochadel M, Frankenstein L, Pauschinger M, Hambrecht R, et al.
Clin Res Cardiol
. 2024 May;
PMID: 38717480
Background: There is scarce information about the influence of prior myocardial infarction (pMI) on outcomes in patients (pts) with ischaemic HFrEF. We analysed data from the EVIdence based TreAtment in...
5.
Wienbergen H, Fach A, Winzer E, Schmucker J, Hanses U, Retzlaff T, et al.
Clin Res Cardiol
. 2023 Aug;
PMID: 37648751
Aims: Educational attainment might impact secondary prevention after myocardial infarction (MI). The purpose of the present study was to compare the rate of risk factors and the efficacy of an...
6.
Hanses U, Diehl K, Ammar A, Dierks P, Alo S, Fach A, et al.
Am J Cardiol
. 2023 Jul;
202:182-191.
PMID: 37451062
Tricuspid transcatheter edge-to-edge repair (T-TEER) for severe tricuspid regurgitation (TR) emerged as a novel treatment option for patients not amenable to surgery. However, knowledge regarding independent risk factors for a...
7.
Bavendiek U, Grosshennig A, Schwab J, Berliner D, Liu X, Maier L, et al.
Clin Res Cardiol
. 2023 Apr;
112(8):1096-1107.
PMID: 37087503
Background: The present study aimed to develop a simple dosing score when starting the cardiac glycoside digitoxin in heart failure with reduced ejection fraction (HFrEF) employing first data from the...
8.
Wienbergen H, Boakye D, Gunther K, Schmucker J, Marin L, Kerniss H, et al.
Eur J Prev Cardiol
. 2022 Jul;
29(16):2076-2087.
PMID: 35776839
Aims: Family history is a known risk factor for early-onset myocardial infarction (EOMI). However, the role of modifiable lifestyle and metabolic factors in EOMI risk is unclear and may differ...
9.
Schmucker J, Fach A, Osteresch R, Marin L, Retzlaff T, Ruhle S, et al.
BMC Cardiovasc Disord
. 2022 Apr;
22(1):142.
PMID: 35365074
Background: Although the detrimental effects of advanced chronic kidney disease (CKD) on prognosis in coronary artery disease is known, there are few data on the efficacy and safety of modern...
10.
Heer T, von Scheidt M, Boening A, Heyken C, Gusmini F, de Waha A, et al.
Eur J Cardiothorac Surg
. 2022 Feb;
62(3).
PMID: 35138350
Objectives: There are disparities in the adherence to guideline-recommended therapies after coronary artery bypass graft (CABG). We therefore sought to evaluate the effect of guideline-adherent medical secondary prevention on 1-year...